Market Place
Sourcing Support
PepGen 5 mg/kg Ph2 FREEDOM2 Shows Safety Splicing vHOT Data
30 Mar 2026 //
BUSINESSWIRE
PepGen To Participate In The Leerink Global Healthcare Conference
03 Mar 2026 //
PHARMIWEB
PepGen Grants Inducement to New Chief Business Officer
09 Dec 2025 //
PHARMIWEB
PepGen Secures U.S. Patent for Proprietary PGN-EDODM1 Molecule
12 Nov 2025 //
BUSINESSWIRE
Pepgen Reveals Q3 2025 Financials & Corporate Updates
12 Nov 2025 //
BUSINESSWIRE
PepGen to Participate in Upcoming Investor Conferences
03 Nov 2025 //
BUSINESSWIRE
Pepgen Presents At 30th World Muscle Society Congress
02 Oct 2025 //
BUSINESSWIRE
PepGen Reports Record Splicing Correction In DM1 Patients
24 Sep 2025 //
BUSINESSWIRE
PepGen Announces Proposed Public Offering
24 Sep 2025 //
BUSINESSWIRE
PepGen Announces Pricing Of $100 Million Public Offering
24 Sep 2025 //
BUSINESSWIRE
PepGen ends all DMD work after ph. 2 trial falls flat
29 May 2025 //
FIERCE PHARMA
PepGen to Focus on DM1 Program After 10 mg/kg PGN-EDO51 Update
28 May 2025 //
BUSINESSWIRE
PepGen pauses UK arm of DMD trial that`s already on hold in US
05 Mar 2025 //
FIERCE BIOTECH
PepGen Announces CONNECT Program Updates
29 Jan 2025 //
BUSINESSWIRE
PepGen Reports Inducement Grant for New Clinical VP Appointment
21 Nov 2024 //
BUSINESSWIRE
PepGen Reports Q3 2024 Financial Results & Corporate Highlights
07 Nov 2024 //
BUSINESSWIRE
PepGen Announces Presentations At World Muscle Society Congress
08 Oct 2024 //
BUSINESSWIRE
PepGen Announces Christopher Ashton To Retire From Board
19 Sep 2024 //
BUSINESSWIRE
PepGen Appoints Paul Streck As Executive VP, Head Of R&D
20 Aug 2024 //
BUSINESSWIRE
PepGen Announces Inducement Grant For Newly Appointed R&D Executive
20 Aug 2024 //
BUSINESSWIRE
PepGen Reports Q2 2024 Results And Corporate Highlights
08 Aug 2024 //
BUSINESSWIRE
PepGen Reports Positive Data From PGN-EDO51 Phase 2 Trial In DMD
30 Jul 2024 //
BUSINESSWIRE
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1
20 Feb 2024 //
GLOBENEWSWIRE
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
07 Feb 2024 //
GLOBENEWSWIRE
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
17 Jan 2024 //
GLOBENEWSWIRE
PepGen Announces First Patient Dosed in CONNECT1-EDO51 PII of PGN-EDO51
08 Jan 2024 //
GLOBENEWSWIRE
PepGen Announces First Patient Dosed in Phase 1 Trial of PGN-EDODM1
18 Dec 2023 //
GLOBENEWSWIRE
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
15 Nov 2023 //
GLOBENEWSWIRE
PepGen Announces FDA has Lifted Clinical Hold on IND Application for PGN-EDODM1
12 Oct 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Presentations at the 28th Annual Congress
27 Sep 2023 //
GLOBENEWSWIRE
PepGen Presents PGN-EDODM1 Data Supporting the Company`s Enhanced Delivery
06 Sep 2023 //
GLOBENEWSWIRE
PepGen Announces Clearance of CTA by Health Canada to Begin PI of PGN-EDODM1
06 Sep 2023 //
GLOBENEWSWIRE
PepGen Announces Presentations at Myotonic Dystrophy Annual Conference
01 Sep 2023 //
GLOBENEWSWIRE
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1
13 Jun 2023 //
GLOBENEWSWIRE
PepGen tumbles after FDA hold notice on myotonic dystrophy study
31 May 2023 //
BIOSPACE
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application
30 May 2023 //
GLOBENEWSWIRE
PepGen Announces Clearance by Health Canada for PGN-EDO51 to Begin Phase 2 Trial
18 May 2023 //
GLOBENEWSWIRE
PepGen to Participate in the Bank of America Securities 2023 Conference
04 May 2023 //
GLOBENEWSWIRE
